Versartis, Inc.
Biotechnology ResearchTexas, United States11-50 Employees
Aravive, Inc. is a late clinical-stage oncology company developing transformative, targeted therapeutics to treat metastatic disease. The company is based in Houston, Texas, and has a satellite offices in the Research Triangle Park area in NC. and Bethesda, MD. For more information, please visit our website at http://www.aravive.com. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Dr. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer’s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.
1-888-653-2347 
support@leadiq.com 
